Oil dips as soaring US production outweighs talk of OPEC output cuts


Oil dips as soaring US production outweighs talk of OPEC output cuts Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-11-08
Keywords: news, cnbc, companies, dips, oil, output, talk, opec, cuts, outweighs, soaring, production



Company: cnbc, Activity: cnbc, Date: 2018-11-08
Keywords: news, cnbc, companies, dips, oil, output, talk, opec, cuts, outweighs, soaring, production


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

Buffett-owned DaVita plunges 9% after soaring on midterm elections

DaVita shares plunged more than 9 percent Thursday, threatening to erase all of the dialysis provider’s gains the day before. Investors sold off DaVita after the Denver-based company reported late Wednesday third-quarter earnings of 56 cents per share on revenue of $2.85 billion, missing Wall Street projections on both. Analysts had expected earnings of 87 cents per share and $2.93 billion in revenue, according to data compiled by Refinitiv. The ballot measure would have capped the amount of mon


DaVita shares plunged more than 9 percent Thursday, threatening to erase all of the dialysis provider’s gains the day before. Investors sold off DaVita after the Denver-based company reported late Wednesday third-quarter earnings of 56 cents per share on revenue of $2.85 billion, missing Wall Street projections on both. Analysts had expected earnings of 87 cents per share and $2.93 billion in revenue, according to data compiled by Refinitiv. The ballot measure would have capped the amount of mon
Buffett-owned DaVita plunges 9% after soaring on midterm elections Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-11-08  Authors: berkeley lovelace jr, joe amon, the denver post, getty images
Keywords: news, cnbc, companies, soaring, buffettowned, measure, davita, earn, state, million, providers, share, elections, midterm, revenue, shares, plunges, earnings, dialysis


Buffett-owned DaVita plunges 9% after soaring on midterm elections

DaVita shares plunged more than 9 percent Thursday, threatening to erase all of the dialysis provider’s gains the day before.

Investors sold off DaVita after the Denver-based company reported late Wednesday third-quarter earnings of 56 cents per share on revenue of $2.85 billion, missing Wall Street projections on both. Analysts had expected earnings of 87 cents per share and $2.93 billion in revenue, according to data compiled by Refinitiv.

The disappointing earnings erased almost all of the 9.9 percent rally in the shares Wednesday after California voters rejected a measure that would have cut into the company’s profits.

Warren Buffett’s Berkshire Hathaway owns a 23 percent stake in DaVita.

The ballot measure would have capped the amount of money dialysis providers in the state can earn on treating certain patients.

Pushed by the Service Employees International Union, the measure would have limited the revenue dialysis providers could earn through rates from privately insured patients to 115 percent of the costs to provide the care.

DaVita, which operates half of all the chronic dialysis clinics in the state, had shelled out $66.6 million of the more than $110 million spent by the industry lobbying against Proposition 8.

WATCH:Why you shouldn’t panic when stocks are getting slammed


Company: cnbc, Activity: cnbc, Date: 2018-11-08  Authors: berkeley lovelace jr, joe amon, the denver post, getty images
Keywords: news, cnbc, companies, soaring, buffettowned, measure, davita, earn, state, million, providers, share, elections, midterm, revenue, shares, plunges, earnings, dialysis


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

The global economic impact of $100 oil ‘isn’t trivial’: Here are the likely winners and losers

The prospect of an abrupt supply shock in the energy market is making investors increasingly nervous about the possibility of oil prices soaring above $100 a barrel before year-end. Oil prices have surged more than 25 percent this year, prompting investors to bet that a return to triple-digits could be just around the corner. It comes as market players closely monitor a flurry of supply concerns, with looming U.S. sanctions against Iran, bottlenecks building in the U.S. shale industry and the co


The prospect of an abrupt supply shock in the energy market is making investors increasingly nervous about the possibility of oil prices soaring above $100 a barrel before year-end. Oil prices have surged more than 25 percent this year, prompting investors to bet that a return to triple-digits could be just around the corner. It comes as market players closely monitor a flurry of supply concerns, with looming U.S. sanctions against Iran, bottlenecks building in the U.S. shale industry and the co
The global economic impact of $100 oil ‘isn’t trivial’: Here are the likely winners and losers Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-10-11  Authors: sam meredith, nick oxford, kaveh kazemi, getty images
Keywords: news, cnbc, companies, oil, upside, losers, venezuelas, tripledigits, supply, impact, global, yearendoil, soaring, surged, trivial, winners, prices, investors, 100, isnt, market, likely, economic


The global economic impact of $100 oil 'isn't trivial': Here are the likely winners and losers

The prospect of an abrupt supply shock in the energy market is making investors increasingly nervous about the possibility of oil prices soaring above $100 a barrel before year-end.

Oil prices have surged more than 25 percent this year, prompting investors to bet that a return to triple-digits could be just around the corner.

It comes as market players closely monitor a flurry of supply concerns, with looming U.S. sanctions against Iran, bottlenecks building in the U.S. shale industry and the collapse of Venezuela’s economy all intensifying an upside risk in the market.


Company: cnbc, Activity: cnbc, Date: 2018-10-11  Authors: sam meredith, nick oxford, kaveh kazemi, getty images
Keywords: news, cnbc, companies, oil, upside, losers, venezuelas, tripledigits, supply, impact, global, yearendoil, soaring, surged, trivial, winners, prices, investors, 100, isnt, market, likely, economic


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

GE shares are soaring, but at least one technician sees a ‘dead cat bounce’

3:08 PM ET Fri, 5 Oct 2018 | 02:48GE is coming off its best week in nearly a decade. “Let’s call it a fundamental reshuffling and you’re getting a technical dead cat bounce from this,” Bill Baruch, president of Blue Line Futures, told CNBC’s “Trading Nation” on Friday. A “dead cat bounce” is when a stock sees a short-lived rally following a sharp and sustained decline. “What I would say is more than just a dead cat bounce would be a move above its 200-day moving average at $14.14,” said Baruch.


3:08 PM ET Fri, 5 Oct 2018 | 02:48GE is coming off its best week in nearly a decade. “Let’s call it a fundamental reshuffling and you’re getting a technical dead cat bounce from this,” Bill Baruch, president of Blue Line Futures, told CNBC’s “Trading Nation” on Friday. A “dead cat bounce” is when a stock sees a short-lived rally following a sharp and sustained decline. “What I would say is more than just a dead cat bounce would be a move above its 200-day moving average at $14.14,” said Baruch.
GE shares are soaring, but at least one technician sees a ‘dead cat bounce’ Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-10-08  Authors: keris lahiff, getty images, sebastien bozon, afp, frederic j brown, kcna, thomas barwick getty images, source, lawrence mcdonald
Keywords: news, cnbc, companies, rally, best, dead, bounce, ge, nearly, technician, cat, shares, sees, stock, problems, technical, soaring, ceo


GE shares are soaring, but at least one technician sees a 'dead cat bounce'

GE just posted its best week in nearly a decade. Is the worst over? 3:08 PM ET Fri, 5 Oct 2018 | 02:48

GE is coming off its best week in nearly a decade.

The one-time Dow stock ended Friday with a weekly gain of more than 17 percent, its best since March 2009, after a CEO shakeup last week.

One technical analyst says this rebound could prove nothing more than temporary.

“Let’s call it a fundamental reshuffling and you’re getting a technical dead cat bounce from this,” Bill Baruch, president of Blue Line Futures, told CNBC’s “Trading Nation” on Friday.

A “dead cat bounce” is when a stock sees a short-lived rally following a sharp and sustained decline. At its lows in late September, GE was 55 percent off its 52-week high set last October. Even after last week’s gains, it remains 46 percent from that high.

This recovery could turn into a bigger breakout if it can break through one key technical level, according to Baruch.

“What I would say is more than just a dead cat bounce would be a move above its 200-day moving average at $14.14,” said Baruch. “If that does [happen], you could see a rise back to about unchanged on the year.”

GE would need to rally 7 percent to break through its 200-day moving average at $14.06. A move back to unchanged for the year at $17.45 represents a 32 percent rally from Friday’s level. The stock was up nearly 2 percent at $13.44 in Monday’s premarket after an upgrade by Barclays.

The embattled industrial giant cut loose CEO John Flannery last Monday, replacing him with former Danaher chief Larry Culp. The change in C-suite leadership swept its shares back up to early August highs.

One market watcher says the fundamentals haven’t changed enough to support a full recovery.

“The problem is a lot of the problems that investors had with the prior CEO were problems that he inherited and didn’t necessarily create,” Erin Gibbs, portfolio manager at S&P Global Market Intelligence, said of Flannery.

Culp faces similar issues that plagued Flannery’s tenure, Gibbs continued.

He has “some major headwinds facing him, particularly with the asset write-downs and the problems with the power business,” she said. “We just don’t see that turnaround, and I don’t see that a new CEO is going to be that key to turning the ship around just yet.”

Flannery held the CEO position for just over a year. From the announcement of his appointment in mid-June 2017 to his dismissal this year, the stock tumbled nearly 60 percent.


Company: cnbc, Activity: cnbc, Date: 2018-10-08  Authors: keris lahiff, getty images, sebastien bozon, afp, frederic j brown, kcna, thomas barwick getty images, source, lawrence mcdonald
Keywords: news, cnbc, companies, rally, best, dead, bounce, ge, nearly, technician, cat, shares, sees, stock, problems, technical, soaring, ceo


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

Tesla shares are soaring. Five experts weigh in on what comes next

Here’s what five experts just said about Tesla shares and the electric auto maker’s divisive leader:”We can all disagree on some of the tactics that [Musk] does, but he’s certainly a visionary. And I think, now, it’s really, let’s see if they can execute,” said Brad Gastwirth, founder and CEO of ABR Investment Strategy. I can’t imagine a new chairman and new independent board members will not be simpatico with Elon Musk. “I think Tesla at this point still remains a very problematic bet because n


Here’s what five experts just said about Tesla shares and the electric auto maker’s divisive leader:”We can all disagree on some of the tactics that [Musk] does, but he’s certainly a visionary. And I think, now, it’s really, let’s see if they can execute,” said Brad Gastwirth, founder and CEO of ABR Investment Strategy. I can’t imagine a new chairman and new independent board members will not be simpatico with Elon Musk. “I think Tesla at this point still remains a very problematic bet because n
Tesla shares are soaring. Five experts weigh in on what comes next Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-10-01  Authors: rebecca ungarino, lionel bonaventure, afp, getty images, mandel ngan, michael nagle, bloomberg, sebastien bozon, ge renewable energy, kcna
Keywords: news, cnbc, companies, rally, hes, soaring, elon, really, comes, think, sec, ceo, weigh, tesla, musk, shares, experts


Tesla shares are soaring. Five experts weigh in on what comes next

Three experts on the future of Tesla after Elon Musk settled with SEC 18 Hours Ago | 01:35

Tesla shares surged 17 percent on Monday, placing the stock on track for its largest gain in two months after CEO Elon Musk reached a settlement with the U.S. Securities and Exchange Commission on Saturday.

Here’s what five experts just said about Tesla shares and the electric auto maker’s divisive leader:

“We can all disagree on some of the tactics that [Musk] does, but he’s certainly a visionary. He’s done quite well with many different ideas. I think it’s good that he’s still the CEO. I think it’s very good that there’ll be an independent chairman. And I think, now, it’s really, let’s see if they can execute,” said Brad Gastwirth, founder and CEO of ABR Investment Strategy.

“This is a huge opportunity for the board to really bring in somebody from the outside that can gain investor confidence. I hope that they capitalize on that opportunity, because it’s something they couldn’t have done themselves. They need to have their hand forced, and here they are with a gift, essentially,” said Gene Munster, managing partner at Loup Ventures.

Paul Ingrassia, editor at The Revs Institute, said, “The issue here is really, as long as Elon Musk stays as CEO, it’s hard to imagine much of anything changing in that company. You know, he might behave ‘marginally better’ according to the SEC rules. But he’s a pretty strong-willed guy and usually gets his way. He’s pretty much getting his way on this. I can’t imagine a new chairman and new independent board members will not be simpatico with Elon Musk. So, again, this is sort of like the new trade deal: When all is said and done, much more was said than was done.”

“I think Tesla at this point still remains a very problematic bet because now that they have settled charges with the SEC, Elon Musk is essentially reined in on any dramatic commentary that he can make. And now the market focus is going to be much more on the fundamentals, and the basic blocking and tackling of actually producing cars. And to that end, the company is still missing its estimates by about 20 percent going forward. So it’s hard to imagine that you’re going to have too much upside here, unless they have dramatic increases in production and delivery and logistics before you can really make a strong bet that Tesla is still a buy at this level,” said Boris Schlossberg, managing director of foreign exchange strategy at BK Asset Management.

Craig Johnson, chief market technician at Piper Jaffray, said, “Shares of Tesla to us look like one gigantic relief rally for a couple of reasons. First, the shares have underperformed the S&P 500 over the last 12 months. Second, when I look at this bounce we’ve seen here in the shares, they were oversold coming into today’s price action, and all we’ve done so far is rally right back up into the declining 200-day moving average. And lastly, we’d be using this strength to reduce our position in Tesla, as we think a lot of other stock have better management teams and look more attractive on an upside basis.”

Bottom line: Investors should wait to see what kind of progress the Tesla board can make on gaining investor confidence following Musk’s settlement, and from a technical standpoint the rally on Monday may simply be a relief rally and nothing more.


Company: cnbc, Activity: cnbc, Date: 2018-10-01  Authors: rebecca ungarino, lionel bonaventure, afp, getty images, mandel ngan, michael nagle, bloomberg, sebastien bozon, ge renewable energy, kcna
Keywords: news, cnbc, companies, rally, hes, soaring, elon, really, comes, think, sec, ceo, weigh, tesla, musk, shares, experts


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

The pot stocks are soaring again after a CBD-based drug took a step closer to commercial launch

“We continue to recommend the stock on the basis that we believe the Epidiolex launch can exceed first year expectations,” the analyst added. News of the mild DEA classification comes amid growing fascination on Wall Street over a handful of companies engaged in the cultivation and production of cannabis products for either medical or nonmedical purposes. Other stocks in the limelight include pharmaceutical companies, including GW Pharmaceuticals, that produce and market drugs that use cannabino


“We continue to recommend the stock on the basis that we believe the Epidiolex launch can exceed first year expectations,” the analyst added. News of the mild DEA classification comes amid growing fascination on Wall Street over a handful of companies engaged in the cultivation and production of cannabis products for either medical or nonmedical purposes. Other stocks in the limelight include pharmaceutical companies, including GW Pharmaceuticals, that produce and market drugs that use cannabino
The pot stocks are soaring again after a CBD-based drug took a step closer to commercial launch Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-09-27  Authors: thomas franck, cole burston, getty images
Keywords: news, cnbc, companies, pot, commercial, dea, launch, step, medical, cannabis, cbdbased, gw, market, stocks, wall, drug, street, companies, soaring, took, closer


The pot stocks are soaring again after a CBD-based drug took a step closer to commercial launch

Six experts on whether the cannabis craze is a boom or bust 8:04 PM ET Tue, 25 Sept 2018 | 04:49

This announcement “renders the launch set-up fairly straightforward for GW into a market where there is significant unmet medical need and very high pent up awareness/demand,” wrote Stifel analyst Paul Mattela.

“We continue to recommend the stock on the basis that we believe the Epidiolex launch can exceed first year expectations,” the analyst added.

News of the mild DEA classification comes amid growing fascination on Wall Street over a handful of companies engaged in the cultivation and production of cannabis products for either medical or nonmedical purposes.

Other stocks in the limelight include pharmaceutical companies, including GW Pharmaceuticals, that produce and market drugs that use cannabinoids.

Tilray, for example, enthralled Wall Street last week after posting its best day ever following approval from the Drug Enforcement Administration to import pot to the United States for medical research.

Given the excitement around what appears to be an amenable DEA, Tilray shares have swung wildly over the last 10 days as investors are pinned between interest in a stake in the burgeoning industry and fears of an asset bubble.

Though both Aurora Cannabis and Canopy Growth — two other marijuana plays — traded lower Thursday, both stocks have endured similar frenzy over the last few weeks.

Aurora has rallied 35 percent this month in Canadian trading after Canadian news service BNN Bloomberg reported Coca-Cola is in talks with Aurora to develop weed-infused beverages.


Company: cnbc, Activity: cnbc, Date: 2018-09-27  Authors: thomas franck, cole burston, getty images
Keywords: news, cnbc, companies, pot, commercial, dea, launch, step, medical, cannabis, cbdbased, gw, market, stocks, wall, drug, street, companies, soaring, took, closer


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

Pot stocks are soaring again with Tilray surging 40% in early trading

The SEC is warning about pot stocks, and the reasons are similar to those for cryptocurrencies 5:47 PM ET Fri, 7 Sept 2018 | 05:17Kennedy argued that the same can be said for food and beverage companies. Aurora Cannabis has rallied nearly 30 percent this week in Canadian trading after Canadian news service BNN Bloomberg reported Coca-Cola is in talks with Aurora to develop weed-infused beverages. Quickly becoming one of Wall Street’s most-followed stocks of 2018, Tilray posted its second-best da


The SEC is warning about pot stocks, and the reasons are similar to those for cryptocurrencies 5:47 PM ET Fri, 7 Sept 2018 | 05:17Kennedy argued that the same can be said for food and beverage companies. Aurora Cannabis has rallied nearly 30 percent this week in Canadian trading after Canadian news service BNN Bloomberg reported Coca-Cola is in talks with Aurora to develop weed-infused beverages. Quickly becoming one of Wall Street’s most-followed stocks of 2018, Tilray posted its second-best da
Pot stocks are soaring again with Tilray surging 40% in early trading Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-09-19  Authors: thomas franck
Keywords: news, cnbc, companies, aurora, surging, trading, companys, soaring, million, shares, pot, 2018, 40, early, stocks, tilray, physicians, canadian, cannabis


Pot stocks are soaring again with Tilray surging 40% in early trading

The SEC is warning about pot stocks, and the reasons are similar to those for cryptocurrencies 5:47 PM ET Fri, 7 Sept 2018 | 05:17

Kennedy argued that the same can be said for food and beverage companies. Aurora Cannabis has rallied nearly 30 percent this week in Canadian trading after Canadian news service BNN Bloomberg reported Coca-Cola is in talks with Aurora to develop weed-infused beverages.

Quickly becoming one of Wall Street’s most-followed stocks of 2018, Tilray posted its second-best day ever since its IPO on Tuesday after announcing approval from the Drug Enforcement Administration to import pot to the United States for medical research.

The company’s U.S.-listed shares jumped 29 percent in the prior session with 19 million of the company’s 21.7 million floating shares exchanging hands.

Tilray said Tuesday that it will work with the University of California San Diego Center for Medicinal Cannabis Research to study the safety, tolerability and efficacy of marijuana for a neurological disorder.

“Clinical trials build a halo around the brand. They inspire confidence and trust with physicians and regulators around the world and they give us data and information to talk to pharmacists and physicians that they just can’t obtain from our competitors,” Kennedy said.

Tilray’s market cap, despite the company posting $9.7 million in revenue as of last quarter, is larger than more than one-quarter of the S&P 500.

For reference, the company’s valuation exceeds that of Chipotle and E-Trade.

— CNBC’s Chloe Aiello and Elizabeth Gurdus contributed reporting.


Company: cnbc, Activity: cnbc, Date: 2018-09-19  Authors: thomas franck
Keywords: news, cnbc, companies, aurora, surging, trading, companys, soaring, million, shares, pot, 2018, 40, early, stocks, tilray, physicians, canadian, cannabis


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

As investors chase pot stocks rally, some show caution: ‘This is just stupid time’

There is a new mania infecting the stock market: pot stocks. But many veteran traders and investors are cautious on buying pot stocks after the sector’s surge, saying the frenzy is reminiscent of previous bubbles. Tilray shares are doing even better and have become the poster child of the pot stock frenzy. One investment banker believes the pot stock party is just getting started and predicts more public offerings from the industry. “The race is on and the landscape of large publicly-listed U.S.


There is a new mania infecting the stock market: pot stocks. But many veteran traders and investors are cautious on buying pot stocks after the sector’s surge, saying the frenzy is reminiscent of previous bubbles. Tilray shares are doing even better and have become the poster child of the pot stock frenzy. One investment banker believes the pot stock party is just getting started and predicts more public offerings from the industry. “The race is on and the landscape of large publicly-listed U.S.
As investors chase pot stocks rally, some show caution: ‘This is just stupid time’ Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-09-19  Authors: tae kim, cole burston, getty images
Keywords: news, cnbc, companies, stock, rally, chase, marijuana, shares, trading, caution, stocks, pot, soaring, companies, tilray, stupid, investors, cannabis


As investors chase pot stocks rally, some show caution: 'This is just stupid time'

There is a new mania infecting the stock market: pot stocks.

Cannabis-related names are soaring as companies and investors are clamoring to get exposure to the burgeoning marijuana-legalization trend. But many veteran traders and investors are cautious on buying pot stocks after the sector’s surge, saying the frenzy is reminiscent of previous bubbles.

In June, Canada announced it will legalize recreational marijuana use effective Oct. 17, sparking a series of industry moves. Soon after Canadian marijuana producer Tilray filed for an initial public offering, which occurred in July.

In August, Molson Coors said it will partner with The Hydropothecary Corp. to develop cannabis-infused beverages for the Canadian market. Later that month beer maker Constellation Brands invested an additional $4 billionin Canadian-cannabis producer Canopy Growth.

As a result of the news, pot stocks are soaring. Canopy Growth’s stock has more than doubled this year.

Tilray shares are doing even better and have become the poster child of the pot stock frenzy.

The marijuana producer’s shares are up more than 800 percent since its first day of trading after its July IPO and rose nearly 600 percent in the past month. The stock rallied as much as 94 percent Wednesday, a day after its CEO, Brendan Kennedy, told CNBC’s Jim Cramer that pharmaceutical companies should partner with cannabis producers as a “hedge” against the space. Tilray shares later pared its gains and closed up 38 percent for the trading session after multiple volatility halts.

One investment banker believes the pot stock party is just getting started and predicts more public offerings from the industry.

“Clearly investor appetite for Cannabis companies is on the rise. This is a global sector that is opening up and the early movers are reaping the rewards in their valuations and access to capital,” Canaccord Genuity’s Graham Saunders said in an email Wednesday. “The race is on and the landscape of large publicly-listed U.S. Cannabis companies is about to increase materially.”


Company: cnbc, Activity: cnbc, Date: 2018-09-19  Authors: tae kim, cole burston, getty images
Keywords: news, cnbc, companies, stock, rally, chase, marijuana, shares, trading, caution, stocks, pot, soaring, companies, tilray, stupid, investors, cannabis


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

Analyst says market’s top performer AMD to keep soaring, raises price target to highest on Street

The firm raised its price target for AMD shares to $30 from $27, citing the chipmaker’s process manufacturing advantage versus Intel and Nvidia. The new forecast represents 44 percent upside to Wednesday’s close and is the highest target of the 26 analysts who cover AMD on Wall Street, according to FactSet. “Because of our renewed conviction post-meetings of a multi-year double digit growth profile for AMD we are raising our price target.” AMD shares are up 5.5 percent Thursday after the report.


The firm raised its price target for AMD shares to $30 from $27, citing the chipmaker’s process manufacturing advantage versus Intel and Nvidia. The new forecast represents 44 percent upside to Wednesday’s close and is the highest target of the 26 analysts who cover AMD on Wall Street, according to FactSet. “Because of our renewed conviction post-meetings of a multi-year double digit growth profile for AMD we are raising our price target.” AMD shares are up 5.5 percent Thursday after the report.
Analyst says market’s top performer AMD to keep soaring, raises price target to highest on Street Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-08-23  Authors: tae kim, norbert millauer, afp, getty images
Keywords: news, cnbc, companies, price, versus, amd, advantage, analyst, vs, nanometer, soaring, performer, highest, street, target, shares, amds, sp, intel, markets, raises


Analyst says market’s top performer AMD to keep soaring, raises price target to highest on Street

Rosenblatt Securities is more optimistic about AMD’s future market share gains after meetings with the company’s executives.

The firm raised its price target for AMD shares to $30 from $27, citing the chipmaker’s process manufacturing advantage versus Intel and Nvidia. The new forecast represents 44 percent upside to Wednesday’s close and is the highest target of the 26 analysts who cover AMD on Wall Street, according to FactSet.

“We hosted institutional investor meetings this week in the mid-West and Canada with AMD’s CFO Devinder Kumar and IR Corporate VP Laura Graves. We were impressed by the deep dives long-focused investors are doing in the name after many years of disregard,” analyst Hans Mosesmann said in a note to clients Thursday. “Because of our renewed conviction post-meetings of a multi-year double digit growth profile for AMD we are raising our price target.”

AMD shares are up 5.5 percent Thursday after the report.

Mosesmann noted Intel’s delay in moving to the 10 nanometer chip process. Intel said last month that its 10 nanometer chips will be released for holiday 2019 compared with the launch of AMD’s 7 nanometer products later this year.

One nanometer equals one-billionth of a meter. Smaller nanometer chipmaking technologies historically have allowed companies to create faster, more power-efficient chips.

“AMD never planned or expected Intel to have 10nm delays in their own product planning from years’ back and acknowledges that a historical window of opportunity has opened,” he said. “We believe AMD has a multi-year advantage vs. Intel in CPUs with 7nm and a 6-month plus advantage vs. Nvidia in GPUs for the datacenter.”

The chipmaker’s stock is significantly outperforming the market this year. Its shares are up 103 percent year to date through Wednesday versus the S&P 500’s 7 percent gain. AMD stock’s performance ranks as the top return in the S&P 500 this year.


Company: cnbc, Activity: cnbc, Date: 2018-08-23  Authors: tae kim, norbert millauer, afp, getty images
Keywords: news, cnbc, companies, price, versus, amd, advantage, analyst, vs, nanometer, soaring, performer, highest, street, target, shares, amds, sp, intel, markets, raises


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post

Dow stock Nike is soaring, and charts point to more gains

Nike surged 3 percent Monday, hitting an all-time high on the heels of Piper Jaffray upgrading the stock to overweight from neutral. Lululemon, for its part, surged to its own all-time high after Deutsche Bank raised its price target on the stock. Some investors say Nike — the Dow’s top-performing name this year — and the broader space have more room to run. Another stock to consider in the space is Under Armour, Baruch said Monday on CNBC’s “Trading Nation.” “Warren Buffett says, ‘Invest in wha


Nike surged 3 percent Monday, hitting an all-time high on the heels of Piper Jaffray upgrading the stock to overweight from neutral. Lululemon, for its part, surged to its own all-time high after Deutsche Bank raised its price target on the stock. Some investors say Nike — the Dow’s top-performing name this year — and the broader space have more room to run. Another stock to consider in the space is Under Armour, Baruch said Monday on CNBC’s “Trading Nation.” “Warren Buffett says, ‘Invest in wha
Dow stock Nike is soaring, and charts point to more gains Cached Page below :
Company: cnbc, Activity: cnbc, Date: 2018-08-20  Authors: rebecca ungarino, mike blake, osman orsal, brendan mcdermid, stacy revere, getty images, kcna, thomas barwick getty images, source, lawrence mcdonald
Keywords: news, cnbc, companies, point, charts, think, lululemon, armour, stock, trading, surged, soaring, dow, baruch, nike, space, gains, relative


Dow stock Nike is soaring, and charts point to more gains

These names are giving “active” investing a whole new meaning.

Nike surged 3 percent Monday, hitting an all-time high on the heels of Piper Jaffray upgrading the stock to overweight from neutral. The move sparked a rally in companies like Lululemon, Foot Locker and Under Armour. Lululemon, for its part, surged to its own all-time high after Deutsche Bank raised its price target on the stock.

Some investors say Nike — the Dow’s top-performing name this year — and the broader space have more room to run.

“I like Nike. I think you let it run here. I think you add to it, add to your winners,” Ari Wald, head of technical analysis at Oppenheimer, said Monday on CNBC’s “Trading Nation.”

“I think the key point here is, relative to the S&P 500, the stock is still retracing underperformance dating back to its 2015 relative peak,” he said, adding its relative performance continues rising.

Others echo Wald’s outlook. Nike looks poised to continue rallying here, said Bill Baruch, president of Blue Line Futures. Another stock to consider in the space is Under Armour, Baruch said Monday on CNBC’s “Trading Nation.”

“Warren Buffett says, ‘Invest in what you know,’ and I know Under Armour,” Baruch said, adding his familiarity with the brand gives him his bullish standpoint, and would stick with that stock here.


Company: cnbc, Activity: cnbc, Date: 2018-08-20  Authors: rebecca ungarino, mike blake, osman orsal, brendan mcdermid, stacy revere, getty images, kcna, thomas barwick getty images, source, lawrence mcdonald
Keywords: news, cnbc, companies, point, charts, think, lululemon, armour, stock, trading, surged, soaring, dow, baruch, nike, space, gains, relative


Home Forums

    • Forum
    • Topics
    • Posts
    • Last Post